1. Introduction {#s0005}
===============

Septic shock is a dynamic clinical and biological syndrome ([@bb0025]). Patient outcomes are highly variable, reflecting a complex, time-dependent interplay between inflammation, immunity, pathogen-related factors, patient heterogeneity, and therapeutic interventions. We have attempted to navigate this complexity at the individual patient level by developing biomarker-based models to estimate the probability of poor outcomes in patients with septic shock ([@bb0005], [@bb0090], [@bb0095], [@bb0100], [@bb0050]).

Analogous to longstanding concepts in the oncology field, we contend that understanding baseline probability of poor outcome is fundamental to clinical practice and research in the field of septic shock. Prognostic models that reliably estimate the risk of poor outcome have the potential to serve as tools for enrichment of clinical trials, inform individual patient decision-making, to serve as a benchmark for quality improvement efforts, and to facilitate risk-stratified analyses of clinical data. Further, such models have the potential to provide insight regarding the pathogenesis of septic shock and how it varies among different patients.

The Pediatric Sepsis Biomarker Risk Model (PERSEVERE) incorporates a panel of biomarkers and age into a decision tree estimating the baseline risk of mortality in children with septic shock ([@bb0090], [@bb0100]). The PERSEVERE biomarkers are proteins measured in the blood compartment on day 1 of presentation to the intensive care unit with septic shock. To reflect change in risk over time, we developed a temporal version of the model (tPERSEVERE) ([@bb0105]). tPERSEVERE considers how the PERSEVERE biomarker concentrations change from day 1 to day 3 of septic shock, and how these changes are associated with poor outcome.

We envisioned that a reliable temporal model could potentially serve as a monitor for therapeutic efficacy, in combination with traditional clinical parameters. For example, if the model signals a decreasing risk for poor outcome over time, this could be indicative of therapeutic efficacy. Alternatively, if the model signals increasing risk or unchanged risk from a high baseline risk, this could indicate lack of efficacy and could potentially trigger a reassessment of the therapeutic regimen.

Models such as tPERSEVERE require prospective testing in order to assess validity and generalizability. In the current study, we prospectively tested the performance of tPERSEVERE in an independent validation cohort, and use the results to explore how biological variation may be associated with the pathogenesis of poor outcomes in septic shock.

2. Methods {#s0010}
==========

2.1. Study Subjects and Data Collection {#s0015}
---------------------------------------

The validation cohort consisted of 168 subjects prospectively enrolled since the initial derivation of tPERSEVERE. The protocol for collection and use of biological specimens and clinical data was approved by the Institutional Review Boards of each of 18 participating institutions. Children ≤ 18 years of age admitted to the pediatric intensive care unit (PICU) and meeting pediatric-specific consensus criteria for septic shock were eligible for enrollment ([@bb0035], [@bb0085]). The only exclusion criterion was the inability to obtain informed consent, which was obtained from parents or legal guardians prior to any data or sample collection.

Serum samples were obtained within 24 h of first meeting the criteria for septic shock in the PICU, which was typically at presentation. These are referred to as "day 1" samples. "Day 3" samples were collected 48 h after the day 1 samples. Clinical and laboratory data were collected daily while in the PICU. Organ failure data were tracked up to day seven of septic shock using previously published criteria ([@bb0035]). Mortality was tracked for 28 days after enrollment. Complicated course was defined as the persistence of two or more organ failures at day seven of septic shock or 28-day mortality ([@bb0110]). Illness severity was estimated using PRISM scores ([@bb0060]). Baseline mortality probability was estimated using PERSEVERE ([@bb0090], [@bb0100]).

2.2. PERSEVERE Biomarkers {#s0020}
-------------------------

PERSEVERE includes C--C chemokine ligand 3 (CCL3), interleukin 8 (IL8), heat shock protein 70 kDa 1B (HSPA1B), granzyme B (GZMB), and matrix metallopeptidase 8 (MMP8) ([@bb0090]). Serum concentrations of these biomarkers were measured using a multi-plex magnetic bead platform (MILLIPLEX™ MAP, EMD Millipore Corporation, Billerica, MA). Biomarker concentrations were measured in a Luminex® 100/200 System (Luminex Corporation, Austin, TX), according the manufacturers\' specifications. Assay performance data were previously published ([@bb0090]).

2.3. Statistical Analysis and Validation of tPERSEVERE {#s0025}
------------------------------------------------------

Initially, data are described using medians, interquartile ranges, frequencies, and percentages. Comparisons between groups used the Mann--Whitney U-test, Chi-square, or Fisher\'s exact tests as appropriate. Descriptive statistics and comparisons used SigmaStat Software (Systat Software, Inc., San Jose, CA).

Each study subject was assigned a probability of a complicated course using the previously published tPERSEVERE model ([@bb0105]). tPERSEVERE performance is reported using diagnostic test statistics with 95% confidence intervals computed using SPSS 23.0 (IBM Corporation, Armonk, NY), R (base version 3.1.1) and package epiR (version 0.9--62) ([@bb0065], [@bb0080]).

2.4. Redesigning tPERSEVERE {#s0030}
---------------------------

*A priori*, we determined that if the area under the receiver operating curve was less than 0.7 in the validation cohort, we would redesign tPERSEVERE. Initially, we explored reasons for failure by comparing the validation cohort to the original cohort, and by characterizing false negatives and comparing them to true positives. Then, to redesign tPERSEVERE we combined the 168 prospectively enrolled subjects, and the 299 previously reported subjects. From this pooled cohort (n = 467) we randomly selected 80% of the subjects for a training cohort (n = 374) and the remaining 20% were retained as a test cohort (n = 93).

The modeling procedures for redesigning tPERSEVERE used CART methodology (Salford Predictive Modeler v6.6, Salford Systems, San Diego, CA) ([@bb0020], [@bb0055]). The primary outcome variable for the modeling was a complicated course, as defined above ([@bb0110]). Using complicated course as the primary outcome variable allows for the exploration of association between temporal biomarker changes and nuances of sepsis severity beyond the dichotomy of "alive" vs. "dead". Continuous, predictor variables for the modeling procedure included the PERSEVERE-based mortality probability, day 1 and day 3 PERSEVERE biomarker values, age, and a derived variable termed "delta", which subtracted the day 1 value for a given biomarker from the respective day 3 value. Dichotomous predictor variables included gender, and the presence of any co-morbidity, malignancy, immune suppression, or previous bone marrow transplantation. Weighting of cases and the addition of cost for misclassification were not used in the modeling procedures. The code and data used to generate the model is available from the authors.

2.5. Funding {#s0035}
------------

The study was funded by the National Institutes of Health, National Institute of General Medical Sciences. The funder played no other role in the study, in the writing of the manuscript, or in the decision to submit the manuscript.

3. Results {#s0040}
==========

3.1. Prospective Validation of tPERSEVERE {#s0045}
-----------------------------------------

[Table 1](#t0005){ref-type="table"} shows the demographic and clinical characteristics of the validation cohort (n = 168). Sixty-three subjects (38%) had a complicated course. Among these, 25 (40%) died by study day 28. Compared to subjects with a non-complicated course, those in the complicated course group had a higher PRISM score, a higher PERSEVERE mortality probability, and a greater proportion had immune suppression or had undergone previous bone marrow transplantation. No other differences were noted.

The validation cohort subjects were classified according to the tPERSEVERE decision tree. For estimating the probability of a complicated course, tPERSEVERE had an area under the curve (AUC) of 0.67 (95% CI: 0.58--0.75). [Table 2](#t0010){ref-type="table"} shows the diagnostic test characteristics of tPERSEVERE in the validation cohort.

3.2. Failure Analysis {#s0050}
---------------------

The diagnostic test characteristics of tPERSEVERE for estimating the probability of a complicated course in the validation cohort were poor. We therefore conducted analyses to determine what factors may have contributed to the poor performance of tPERSEVERE.

We first compared the clinical characteristics of the study subjects in the original derivation cohort ([@bb0105]). to that of the validation cohort. The validation cohort had a higher prevalence of a complicated course (38%) than the original derivation cohort (23%, p \< 0.001). This difference may have been due to a higher comorbidity burden in the validation cohort, compared to the derivation cohort (68% vs. 42%; p \< 0.05). Of note, a higher proportion of subjects in the validation cohort had immune suppression (25% vs. 13%; p \< 0.05) or malignancy (21% vs. 9%, p \< 0.05), compared to the derivation cohort subjects.

[Table 3](#t0015){ref-type="table"} characterizes the false negative and true positive subjects within the validation cohort. The true positive subjects had a higher median PRISM score and a greater proportion of males, compared to the false negative subjects. No other differences were noted.

3.3. Redesigning tPERSEVERE {#s0055}
---------------------------

tPERSEVERE may have performed poorly in the validation cohort because of differences in the clinical characteristics between the derivation and the validation cohort subjects. Further, the difference in illness severity between the false negative and true positives subjects suggests that tPERSEVERE may not perform well across a wide spectrum of illness severity, as measured by PRISM. We therefore redesigned tPERSEVERE with the goals of improved performance across a diverse cohort of children with septic shock and providing biological insight regarding poor outcomes.

[Table 4](#t0020){ref-type="table"} shows the demographic and clinical characteristics of the training and test sets for the modeling procedures. Subjects in the test set were older and had a higher mortality rate, compared to subjects in the training set. No other differences were noted.

[Fig. 1](#f0005){ref-type="fig"} shows tPERSEVERE based on the training set. Baseline PERSEVERE mortality risk occupied the first level decision rule. Day 1 and day 3 IL8 values, delta IL8, day 1 and day 3 CCL3 values, and day 3 MMP8 values also contributed to the predictive capacity of the redesigned tPERSEVERE model. None of the other predictor variables considered in the modeling process contributed to predictive capacity.

The redesigned tPERSEVERE model had five low risk terminal nodes (0.0% to 15.0% risk of complicated course; nodes 1, 3, 5, 7, and 9), four intermediate risk terminal nodes (28.9% to 46.7% risk of complicated course; nodes 2, 4, 6, and 8), and two high risk terminal nodes (\> 50% risk of complicated course; nodes 10 and 11). Among the 169 subjects classified as low risk, 162 (96%) did not have a complicated course. Among the 117 subjects classified as intermediate risk, 46 (39%) had a complicated course. Among the 88 subjects classified as high risk, 52 (59%) had a complicated course. [Table 5](#t0025){ref-type="table"} shows the diagnostic test characteristics of the redesigned tPERSEVERE model for estimating the risk of a complicated course in the training set.

3.4. Testing the Redesigned tPERSEVERE Model {#s0060}
--------------------------------------------

[Fig. 2](#f0010){ref-type="fig"} shows the classification of the 93 subjects in the test set, according to the redesigned tPERSEVERE model. Among the 46 subjects classified as low risk, 43 (93%) did not have a complicated course. Among the 25 subjects classified as intermediate risk, 25 (36%) had a complicated course. Among the 22 subjects classified as high risk, 14 (64%) had a complicated course. [Table 5](#t0025){ref-type="table"} shows the diagnostic test characteristics of the redesigned tPERSEVERE model for estimating the risk of a complicated course in the test set. Based on the performance of the redesigned tPERSEVERE model, we estimate that if 350 subjects were included in a prospective evaluation and the accuracy remained at 60% with a sensitivity of 93%, the confidence intervals would be sufficiently narrow to conclude validity at about ± 5%.

4. Discussion {#s0065}
=============

Prospective testing of clinical risk models is imperative for assessing validity. We tested the performance of tPERSEVERE prospectively and found that it performed poorly. One possible reason for failure is that the originally derived model was mathematically over fit, without providing any biological insight ([@bb0105]). Another possible reason is that clinical characteristics having the potential to affect the risk of poor outcome differed between the derivation and validation cohorts, including the prevalence of a complicated course. Finally, our failure analysis suggested that tPERSEVERE performed poorly in those subjects with lower PRISM-based illness severity who went on to develop a complicated course. Accordingly, we redesigned tPERSEVERE using a modeling approach that included these potential confounders.

We attempted to account for differences in disease severity by combining the derivation and validation cohorts, and by randomly selecting subjects for training and test sets. This generated two groups of subjects with similar complicated course prevalence. The two groups were also well matched for the majority of clinical variables examined, except for age and mortality. To further account for differences in clinical phenotype, we considered comorbidity variables, age, and gender in the modeling procedures. None of these clinical variables added to the predictive capacity of the redesigned tPERSEVERE model.

The original version of tPERSEVERE contains only the absolute day 1 and day 3 PERSEVERE biomarker values. To redesign a better performing model that could also provide biological insight regarding the development of poor outcome in children with septic shock, we considered two additional biomarker-based variables. First, we considered the PERSEVERE-based mortality probability. This is a composite variable reflecting day 1 biomarker values for CCL3, IL8, HSPA1B, GZMB, and MMP8, and age ([@bb0090], [@bb0100]). Second, we considered the possibility that a derived variable reflecting the changes in biomarker values from day 1 to day 3, could provide biological information beyond the absolute day 1 and day 3 biomarker values.

The redesigned tPERSEVERE model performed well in the test set. Beyond risk prediction, we suggest that the redesigned model provides useful biological information regarding the risk of a complicated course in children with septic shock. Current paradigms for understanding the pathophysiology of sepsis place patients into two broad endotypes ([@bb0040], [@bb0045], [@bb0070]). One endotype involves patients with excessive inflammation. In these patients, inflammatory mechanisms intended for the eradication of infection become excessive and thereby cause collateral damage to host tissues, which in turn leads to organ injury and higher risk for poor outcome. The other endotype involves patients with ineffective inflammation and a state of relative immune suppression. These patients are also at risk for poor outcome because they are unable to effectively clear infections or are at risk for secondary infections. These two endotypes represent extremes of a spectrum; it is likely that many patients with sepsis reside somewhere within this spectrum. In addition, many patients move along this spectrum during the course of illness.

IL8 and CCL3 are the major chemokines responsible for recruitment and activation of white blood cells and are thus key mediators of inflammation ([@bb0015]). In murine models of experimental sepsis, the respective homologs for IL8 and CCL3 increase in proportion to sepsis severity ([@bb0030]). Subjects occupying the right side of the redesigned decision tree ([Fig. 1](#f0005){ref-type="fig"}) had an intermediate to high PERSEVERE-based mortality risk. Among these subjects, if IL8 levels remained relatively high on day 3 (\> 450 ng/ml, terminal node 11) or if the day 1 CCL3 level was greater than 100 ng/ml (terminal node 10), there was a greater than 50% probability of a complicated course. Conversely, subjects with a high PERSEVERE-based mortality probability, but a relatively low day 3 IL8 concentration (≤ 450 ng/ml) and a day 1 CCL3 concentration less than 100 ng/ml (terminal node 9), had a much lower probability (15%) of a complicated course. Thus, excessive inflammation in the presence of high baseline risk portends poor outcome, while lesser inflammation despite high baseline risk is associated with diminishing risk. These observations are consistent with the sepsis endotype characterized by excessive inflammation.

Subjects occupying the left side of the redesigned decision tree had a low PERSEVERE-based mortality risk. In these subjects, if IL8 decreased by at least 300 ng/ml from day 1 to day 3, the probability of a complicated course was 6.3% in the context of a day 1 IL8 concentration ≤ 525 ng/ml (terminal node 1), but 44.4% in the context of a relatively high day 1 IL8 concentration (\> 525 ng/ml, terminal node 2). In other words, relatively lower baseline IL8 concentrations that are decreasing portend lower risk than relatively higher baseline IL8 concentrations that are decreasing. This suggests those subjects whose inflammatory state is excessive at baseline do poorly, even though inflammation may be diminishing over the first few days. In these same low-baseline-risk subjects, subjects with a day 1 IL8 concentration \> 125 ng/ml and a day 3 IL8 concentration of \> 350 ng/ml had a 42.8% probability of a complicated course (terminal node 8). These observations are also consistent with the sepsis endotype characterized by excessive inflammation and, in particular, suggest evolving excessive inflammation.

In contrast, subjects occupying terminal nodes 5, 6, and 7 may represent the sepsis endotype characterized by immune suppression. In these subjects higher CCL3 concentrations on day 3 were associated with a low risk of a complicated course (terminal nodes 5 and 7), whereas subjects with relatively lower CCL3 concentrations on day 3 had a higher risk of a complicated course (terminal node 6). It may be that these subjects have insufficient recruitment of white blood cells and therefore had a state of relative immune suppression.

Finally, subjects in terminal nodes 3 and 4 may represent patients along the spectrum of excessive inflammation and immune suppression. These patients are defined initially by a low PERSEVERE-based mortality risk, a relatively low starting IL8 and a low day 3 CCL3 concentration. In these subjects, day 3 MMP8 differentiates between those at low risk and those at intermediate risk of a poor outcome. This is consistent with data from murine models exploring the role of MMP8 in sepsis. In these studies, genetic ablation or pharmacological inhibition of MMP8 conferred a survival advantage in mice subjected to sepsis, and this effect was associated with decreased activation of the pro-inflammatory transcription factor, NF-κB, and other indices of inflammation ([@bb0075], [@bb0010]).

We note the limitations of the study. The process of redesigning and testing the tPERSEVERE model was based on pooling of all available subjects, random selection, and subsequent allocation into training and test sets. This process could have introduced unknown or unintended biases. It is therefore possible that the redesigned model is over fit, despite its good performance in the test set. The redesigned model requires testing with a fully independent validation cohort. Our interpretation of the biological information that the model might be providing is based on existing principles of potential sepsis endotypes and data from murine models of sepsis, but is speculative nonetheless. It will be important in future studies to directly determine the relative states of inflammation and immune suppression in subjects allocated to the respective terminal nodes potentially associated with excessive inflammation or immune suppression.

In conclusion, tPERSEVERE performed poorly upon prospective testing. We identified potential confounders leading to failure, and this prompted a redesign of the tPERSEVERE model using randomly selected training and test sets. The redesigned model performed well in the test set, and is consistent with current paradigms of sepsis endotypes involving excessive inflammation and immune suppression. The redesigned model requires prospective testing in a validation cohort and functional studies to confirm the validity of our interpretations of the biological information provided by the model. Successful validation could position tPERSEVERE as a monitor of therapeutic efficacy in patients with septic shock and as a tool for understanding septic shock endotypes predicated on patterns of inflammation and immunity.
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![The redesigned tPERSEVERE classification tree. The classification tree includes the PERSEVERE-based mortality probability, day 1 and day 3 interleukin 8 (IL8) concentrations, the delta IL8 value, day 1 and day 3 C--C chemokine ligand 3 (CCL3) concentrations, and the day 3 matrix metallopeptidase 8 (MMP8) concentration. The biomarker concentrations are shown in ng/ml. The root node provides the total number of subjects in the training set, and the number of subjects with and without a complicated course, with the respective rates. Each daughter node provides the respective decision rule criterion and the number of subjects with and without a complicated course, with the respective rates. A negative value for a "delta" occurs when the biomarker level is, on average, decreasing. Terminal nodes (TN) TN1, TN3, TN5, TN7, and TN9 are low risk terminal nodes (0.0% to 15.0% risk of complicated course). TN2, TN4, TN6, and TN8 are intermediate risk terminal nodes (28.9% to 46.7% risk of complicated course). TN10 and TN11 are high risk terminal nodes (≥ 50% risk of complicated course).](gr1){#f0005}

![Classification of the test set according to the redesigned tPERSEVERE model. The test set subjects (n = 93) were classified according to the redesigned tPERSEVERE model without any modifications. The same conventions apply to the decision tree as described for [Fig. 1](#f0005){ref-type="fig"}.](gr2){#f0010}

###### 

Demographic and clinical characteristics of the validation cohort.

                                               Non-complicated course   Complicated course
  -------------------------------------------- ------------------------ ---------------------------------------------------
  N (%)                                        105 (63)                 63 (38)
  Median age, years (IQR)                      5.3 (1.8--12.8)          4.8 (1.1--14.9)
  Males, \# (%)                                60 (57)                  37 (59)
  28-day mortality, \# (%)                     0 (0)                    25 (40)
  Median PRISM score (IQR)                     10 (7--15)               13 (8--21)[1](#tf0005){ref-type="table-fn"}
  PERSEVERE mortality probability (95% C.I.)   6.5 (4.6--8.4)           12.9 (9.5--16.3)[2](#tf0010){ref-type="table-fn"}
  \# With gram negative bacteria (%)           27 (26)                  15 (24)
  \# With gram positive bacteria (%)           19 (18)                  14 (22)
  \# With other pathogen isolated (%)          9 (9)                    5 (8)
  \# With no pathogen identified (%)           50 (48)                  29 (46)
  \# With comorbidity (%)                      67 (64)                  47 (75)
  \# With malignancy (%)                       20 (19)                  16 (25)
  \# With immune suppression (%)               20 (19)                  22 (35)[3](#tf0015){ref-type="table-fn"}
  \# With bone marrow transplantation (%)      4 (4)                    10 (16)[3](#tf0015){ref-type="table-fn"}

p \< 0.05 vs. non-complicated course; Rank sum test.

p \< 0.05 vs. non-complicated course; t-test.

p \< 0.05 vs. non-complicated course; Chi-square.

###### 

Test characteristics of tPERSEVERE for estimating the probability of a complicated course in the validation cohort.

  --------------------------- -------------------
  No. of false positives      38
  No. of true positives       42
  No. of true negatives       67
  No. of false negatives      21
  Sensitivity                 67% (54--78)
  Specificity                 64% (54--73)
  Positive predictive value   52% (41--64)
  Negative predictive value   76% (66--84)
  + Likelihood ratio          1.84 (1.35--2.51)
  − Likelihood ratio          0.52 (0.36--0.76)
  AUC                         0.67 (0.58--0.75)
  --------------------------- -------------------

###### 

Comparison of the false negative and true positive subjects in the validation cohort.

  VARIABLE                              False negatives   True positives    p Value
  ------------------------------------- ----------------- ----------------- ---------
  N                                     21                42                =
  PRISM; median (IQR)                   10 (8--14)        17 (8--22)        0.031
  Age; median (IQR)                     4.9 (2.6--13.8)   4.4 (0.8--15.2)   0.370
  Deaths; \# (%)                        5 (24)            20 (48)           0.069
  Males; \# (%)                         8 (38)            29 (69)           0.019
  Malignancy; \# (%)                    6 (29)            10 (23)           0.682
  Immune suppression; \# (%)            5 (24)            17 (40)           0.191
  Bone marrow transplantation; \# (%)   1 (5)             9 (21)            0.144

###### 

Demographic and clinical characteristics of the training and test sets for re-designing tPERSEVERE.

                                               Training set      Test set
  -------------------------------------------- ----------------- -------------------------------------------------
  N                                            374               93
  Median age, years (IQR)                      3.0 (1.0--7.5)    5.6 (1.6--9.9)[1](#tf0020){ref-type="table-fn"}
  Males, \# (%)                                220 (58)          55 (59)
  28-day mortality, \# (%)                     31 (8)            15 (16)[2](#tf0025){ref-type="table-fn"}
  \# with complicated course, (%)              105 (28)          26 (28)
  Median PRISM score (IQR)                     12 (8--20)        11 (8--17)
  PERSEVERE mortality probability (95% C.I.)   9.1 (7.6--10.6)   9.9 (6.9--12.9)
  \# With gram negative bacteria (%)           91 (24)           22 (24)
  \# With gram positive bacteria (%)           85 (23)           20 (22)
  \# With other pathogen isolated (%)          41 (11)           10 (11)
  \# With no pathogen identified (%)           157 (42)          41 (44)
  \# With comorbidity (%)                      194 (52)          46 (49)
  \# With malignancy (%)                       50 (13)           14 (15)
  \# With immune suppression (%)               66 (18)           14 (15)
  \# With bone marrow transplantation (%)      16 (4)            8 (9)

p \< 0.05 vs. training set; Rank sum test.

p \< 0.05 vs. training set; Chi-square.

###### 

Test characteristics of the redesigned tPERSEVERE model for estimating the probability of a complicated course in the training and test sets.

                              Training set        Test set
  --------------------------- ------------------- -------------------
  No. of false positives      107                 24
  No. of true positives       98                  23
  No. of true negatives       162                 43
  No. of false negatives      7                   3
  Sensitivity                 93% (86--97)        88% (69--97)
  Specificity                 60% (54--66)        64% (51--75)
  Positive predictive value   48% (41--55)        49% (34--64)
  Negative predictive value   96% (92--98)        93% (82--99)
  + Likelihood ratio          2.35 (2.01--2.74)   2.47 (1.74--3.50)
  − Likelihood ratio          0.11 (0.05--0.23)   0.18 (0.06--0.53)
  AUC                         0.83 (0.79--0.87)   0.84 (0.75--0.92)
